The follicular lymphomas are indolent diseases that are highly responsive to various
combinations of standard chemotherapy drugs. Nevertheless, until recently, no regimen had
improved patient outcome. The incorporation of effective and well-tolerated monoclonal
antibodies, such as rituximab, into chemoimmunotherapeutic strategies provided the first
evidence that survival of these patients could be prolonged. Nevertheless, follicular
lymphoma remains incurable and characterized by recurrent relapses requiring additional …